KCNMA1 and COVID-19: To identify potential drugs for the treatment of COVID-19 and KIRC co-morbidity, we conducted drug target enrichment analysis with four hub genes (GTSE1, CEACAM4, HECW2, and KCNMA1) as genetic targets associated with the construction of risk models via cellMiner and DsigDB databases (Tables S3, S4).